| Her |  | |
Rating: 0
|

|
Registrado: 02/03/2007
Mensajes: 2930
|
On-Line: OFF
| |
Mi cartera sigue igual, con los mismos 7 valores....
Publicado: 02/02/2012 - 22:12
|
Mantengo CTIC (comprada a 1,22$, ha cerrado en 1,05$), GSAT (comprada a 0,53$, ha cerrado en 0,665$), PEIX (comprada a 1,15$, ha cerrado a 1,09$, CYTR (comprada a 0,273, ha cerrado a 0,285$), NGSX (comprada a 0,889, hA CERRADO A 1,05$), ALXA (comprada a 0,75$, ha cerrado a 0,78$), y por último, CPRX (comprada a 1,08$, ha cerrado a 1,08$).
Mi balance sigue siendo el mismo, es decir, 119 euros en negativo, por culpa de las TRIDQ...y la madre que las trajo...
ALXA, tiene el ADASUVE en fase 3, pendiente de FDA en mayo....pero tiene el AZ-104 y el AZ-002 en fase II, aparte de el AZ-003 y AZ-007 en fase I, y un producto en preclinical (staccato nicotine)
Pongo un post de investorshub.... Alexza has a market cap of $53.4 million and an enterprise value of $38.7 million. This stocks trades at a price-to-sales of 1.17. Its estimated growth rate for the next quarter is 21.4%, and for next year it’s pegged at 22.4%. This is a cash-rich company, with a total cash position on its balance sheet of $28.32 million and total debt of $13.64 million. After you back out the debt, Alexza has $14.68 million in cash on the books.
A beneficial owner just bought 179,041 shares, or about $145,000 worth of stock, at 80 cents per share. It looks like this purchase was part of a private placement for Occitan Capital management, which is a 10% owner of Alexza.
From a technical standpoint, ALXA is currently trading below both its 50-day and 200-day moving averages, which is bearish. This stock dropped from its November high of $1.48 to a recent low of 51 cents per share. After hitting that low, the stock has rebounded to a recent high of 99 cents, and it now trades t around 73 cents.
If you‘re a bullish on ALXA, then I would consider looking for long-biased trades once this stock breaks out above 80 cents per shares with big volume. Look for volume that’s near or well above its three-month average action of 1.02 million shares. You could also buy it off any weakness and anticipate the breakout with a mental stop just below 70 cents per share. I would then add to any long positions once ALXA takes out its 50-day moving average of 89 cents per share with heavy volume.
http://stockpickr.com/5-stocks-insiders-are-loading.html-0
CPRX, aparte de 3 productos en fase II, tiene uno, el CPP-115, dirigido a la epilepsia, que está en fase I, cyos resultados se presentarán a finales de marzo, y que ha obtenido la calificación de fast track developpment program por la FDA...
Adjunto un comentario de ihubs... With the next catalyst several months off (the CPP-115 phase 1 results), the price action is pretty much par for the course. The lack of news combined with low float and lack of liquidity likely means we are range bound for the next few months. Of course, that same low float can also work in ones favor as new buyers discover the stock.
CTIC, evidentemente, todo va a depender bastante de lo que suceda con el PIXUVRI, la EMEA y la FED, aunque también tiene el Tosedostat en fase II, el Opaxio en III y el Brostallicin en II....
CYTR, tiene 5 productos en fase II...lo que me mosquea es el tema ese del desliste el 17/2...
NGSX, tiene cita con la FDA el próximo 9 de febrero, por lo que debería subir ante la proximidad de dicha cita...Tiene un producto en fase 3, otro en fase 3 y varios preclinical...
GSAT, pues la que mejor me está funcionando.... a ver si no se tuerce y vendo cerca del dólar....
PEIX, aguantando por encima del dólar....a ver si con los resultados se va a los 2$....
Un saludo
| |